Document Type : Original Article

Authors

Personalized Medicine Research Center of AmitisGen, Tehran, Iran

10.21859/pmj01037

Abstract

Diabetes Mellitus is defined as a metabolic disorder characterized by chronic hyperglycemia. The more prevalent form, type 2 diabetes, usually begins as insulin resistance, a disorder in which the cells do not use insulin properly. T2DM is a complex multifactorial disease in which multiple genetic variants interact with environmental factors to trigger the disease. There is sufficient evidence that T2DM has a strong genetic basis. One of the identified candidate genes associated with type 2 diabetes is CDKAL1, reduced expression of CDKAL1 would result in enhanced activity of CDK5 in β cells, which would lead to decreased insulin secretion. In this study, the association of polymorphism rs10946398 of CDKAL1 with type 2 diabetes was evaluated in 200 people by RFLP-PCR method. No significant association was found between the genotypes of polymorphism rs10946398 and type 2 diabetes in the target population. It is suggested that this polymorphism association with type 2 diabetes in larger populations evaluated.

Keywords

REFERENCE
1. American Diabetes Association. Classification and Diagnosis
of Diabetes. Diabetes Care. 2016;39(Supplement 1):S13-S22.
doi: 10.2337/dc16-S005
2. American Diabetes A. Diagnosis and classification of diabetes
mellitus. Diabetes Care. 2014;37 Suppl 1:S81-90. doi:
10.2337/dc14-S081 pmid: 24357215
3. Cohen P. The twentieth century struggle to decipher insulin
signalling. Nat Rev Mol Cell Biol. 2006;7(11):867-873. doi:
10.1038/nrm2043 pmid: 17057754
4. Rother KI. Diabetes treatment--bridging the divide. N Engl J
Med. 2007;356(15):1499-1501. doi: 10.1056/NEJMp078030
pmid: 17429082
5. Medici F, Hawa M, Ianari A, Pyke DA, Leslie RD.
Concordance rate for type II diabetes mellitus in monozygotic
twins: actuarial analysis. Diabetologia. 1999;42(2):146-150.
doi: 10.1007/s001250051132 pmid: 10064093
6. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes:
pathogenesis and treatment. Lancet. 2008;371(9631):2153-
2156. doi: 10.1016/S0140-6736(08)60932-0 pmid:
18586159
7. Takeuchi F, Serizawa M, Yamamoto K, Fujisawa T, Nakashima
E, Ohnaka K, et al. Confirmation of multiple risk Loci and
genetic impacts by a genome-wide association study of type 2
diabetes in the Japanese population. Diabetes.
2009;58(7):1690-1699. doi: 10.2337/db08-1494 pmid:
19401414
8. Zhou B, Wei FY, Kanai N, Fujimura A, Kaitsuka T, Tomizawa
K. Identification of a splicing variant that regulates type 2
diabetes risk factor CDKAL1 level by a coding-independent
mechanism in human. Hum Mol Genet. 2014;23(17):4639-
4650. doi: 10.1093/hmg/ddu184 pmid: 24760768
9. Ubeda M, Rukstalis JM, Habener JF. Inhibition of cyclin-
dependent kinase 5 activity protects pancreatic beta cells from
glucotoxicity. J Biol Chem. 2006;281(39):28858-28864. doi:
10.1074/jbc.M604690200 pmid: 16887799
10. Steinthorsdottir V, Thorleifsson G, Sulem P, Helgason H,
Grarup N, Sigurdsson A, et al. Identification of low-frequency
and rare sequence variants associated with elevated or reduced
risk of type 2 diabetes. Nat Genet. 2014;46(3):294-298. doi:
10.1038/ng.2882 pmid: 24464100
11. Wood AR, Tyrrell J, Beaumont R, Jones SE, Tuke MA, Ruth
KS, et al. Variants in the FTO and CDKAL1 loci have recessive
effects on risk of obesity and type 2 diabetes, respectively.
Diabetologia. 2016;59(6):1214-1221. doi: 10.1007/s00125-
016-3908-5 pmid: 26961502
12. Wellcome Trust Case Control C. Genome-wide association
study of 14,000 cases of seven common diseases and 3,000
shared controls. Nature. 2007;447(7145):661-678. doi:
10.1038/nature05911 pmid: 17554300
13. Ng M, Fleming T, Robinson M, Thomson B, Graetz N,
Margono C, et al. Global, regional, and national prevalence of
overweight and obesity in children and adults during 1980-
2013: a systematic analysis for the Global Burden of Disease
Study 2013. Lancet. 2014;384(9945):766-781. doi:
10.1016/S0140-6736(14)60460-8 pmid: 24880830.